Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE IN PLASTIC CONTAINER versus FLOWTUSS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE IN PLASTIC CONTAINER versus FLOWTUSS.
AMMONIUM CHLORIDE IN PLASTIC CONTAINER vs FLOWTUSS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant